3 Cash-Heavy Stocks We Approach with Caution [Yahoo! Finance]
Regeneron Pharmaceuticals, Inc. (REGN)
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.regeneron.com
Company Research
Source: Yahoo! Finance
Not all businesses with cash are winners, and that's why we built StockStory - to help you separate the good from the bad. That said, here are three companies with net cash positions to steer clear of and a few alternatives to consider. Net Cash Position: $5.74 billion (7.1% of Market Cap) Founded by scientists who wanted to build a company where science could thrive, Regeneron Pharmaceuticals (NASDAQ:REGN) develops and commercializes medicines for serious diseases, with key products treating eye conditions, allergic diseases, cancer, and other disorders. Why Is REGN Not Exciting? Annual sales growth of 4.3% over the last two years lagged behind its healthcare peers as its large revenue base made it difficult to generate incremental demand Day-to-day expenses have swelled relative to revenue over the last five years as its adjusted operating margin fell by 23.8 percentage points Shrinking returns on capital suggest that increasing competition is eating into the company's
Show less
Read more
Impact Snapshot
Event Time:
REGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
REGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
REGN alerts
High impacting Regeneron Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
REGN
News
- Revamping best-selling drugs to combat patent cliff has limits [Yahoo! Finance]Yahoo! Finance
- Morgan Stanley Sees Policy Risks Receding for Regeneron (REGN) [Yahoo! Finance]Yahoo! Finance
- Vyriad Secures Final $25M Series B Tranche to Advance In Vivo CAR T Candidate into Clinic [Yahoo! Finance]Yahoo! Finance
- Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial AsthmaGlobeNewswire
- Regeneron Announces Presentation at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
REGN
Earnings
- 10/28/25 - Beat
REGN
Sec Filings
- 12/11/25 - Form 4
- 12/11/25 - Form 4
- 12/11/25 - Form 4
- REGN's page on the SEC website